Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 9,584 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacokinetics Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

DSM265 Prophylaxis of Plasmodium Falciparum Malaria

NCT02562872
View directory record Official record
Conditions
Healthy
Interventions
DSM265, Placebo, Sporozoites, Infective mosquito bite
Drug · Biological
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers

NCT02454699
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
MBX400, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity

NCT06568731
View directory record Official record
Conditions
Obesity
Interventions
Danuglipron
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects

NCT02470702
View directory record Official record
Conditions
Healthy
Interventions
Oritavancin, Placebo (D5W)
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Results available

Understanding Dexmedetomidine in Neonates After Open Heart Surgery

NCT00576381
View directory record Official record
Conditions
Tetrology of Fallot, Heart Ventricle, Hypoplastic Left Heart
Interventions
Dexmedetomidine
Drug
Lead sponsor
Athena Zuppa
Other
Eligibility
1 Hour to 30 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Essential Tremor

NCT02978781
View directory record Official record
Conditions
Essential Tremor
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
26
States / cities
Anniston, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

NCT05965219
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Emraclidine, Itraconazole, Carbamazepine, Metformin
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 1, 2026, 10:45 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

NCT06539507
View directory record Official record
Conditions
Netherton Syndrome
Interventions
BCX17725, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
5
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure

NCT02329834
View directory record Official record
Conditions
Heart Failure
Interventions
Fursemide Injection Solution for subcutaneous administration (80 mg), Furosemide Injection, USP
Drug
Lead sponsor
scPharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults

NCT01357811
View directory record Official record
Conditions
Healthy Volunteer
Interventions
eliglustat; digoxin, digoxin
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

NCT01943851
View directory record Official record
Conditions
Neoplasms
Interventions
GSK525762
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Little Rock, Arkansas • Aurora, Colorado • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers

NCT00990145
View directory record Official record
Conditions
MRSA, SSTI
Interventions
EDP-322
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2009 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Results available

AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics

NCT05281601
View directory record Official record
Conditions
SARS-CoV-2
Interventions
AZD7442
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Long Beach, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 1, 2026, 10:45 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

NCT02629692
View directory record Official record
Conditions
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
Interventions
Vodobatinib (K0706) capsules
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
8
States / cities
Downey, California • Los Angeles, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

NCT03346434
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
33
States / cities
Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

NCT03369002
View directory record Official record
Conditions
Hepatic Impairment
Interventions
seladelpar
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional

Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy

NCT02925000
View directory record Official record
Conditions
Cancer
Interventions
TLC178
Drug
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Detroit, Michigan • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

NCT00472836
View directory record Official record
Conditions
Obesity
Interventions
CP-945,598
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Anaheim, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2009 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)

NCT01074944
View directory record Official record
Conditions
Gaucher Disease
Interventions
Eliglustat tartrate
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
10
States / cities
San Diego, California • New Haven, Connecticut • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 1, 2026, 10:45 AM EDT
Not yet recruiting Phase 2 Interventional

The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma

NCT07386002
View directory record Official record
Conditions
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Interventions
Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3
Biological
Lead sponsor
T-MAXIMUM Pharmaceutical Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 1, 2026, 10:45 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006)

NCT06567002
View directory record Official record
Conditions
Healthy
Interventions
MK-6552
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 1, 2026, 10:45 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

NCT05371964
View directory record Official record
Conditions
Myelofibrosis
Interventions
Imetelstat sodium, Ruxolitinib
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Coral Gables, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects

NCT05846009
View directory record Official record
Conditions
Osteochondrodysplasia
Interventions
SAR442501, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 1, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LC542019 in Healthy Subjects and Subjects With T2DM

NCT06333977
View directory record Official record
Conditions
Healthy, Diabetes Mellitus, Type 2
Interventions
LC542019, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 1, 2026, 10:45 AM EDT